tratado_fibro_quistica

136 CRIBADO NEONATAL
24. Crossley JR, Elliott RB, Smith PA. Dried-blood
spot screening for cystic fibrosis in the newborn.
Lancet. 1979;1(8114):472-4.
25. Munck A, Dhondt JL, Sahler C, Roussey M.
Implementation of the French nationwide
cystic fibrosis newborn screening program. J
Pediatr. 2008;153 (2):228-33.
26. Massie J, Clements B; Australian Paediatric
Respiratory Group. Diagnosis of cystic fibrosis
after newborn screening: the Australasian
experience--twenty years and five million
babies later: a consensus statement from the
Australasian Paediatric Respiratory Group.
Pediatr Pulmonol. 2005;39(5):440-6.
27. Korzeniewski SJ, Young WI, Hawkins HC, Cavanagh
K, Nasr SZ, Langbo C, et al. Variation
in immunoreactive trypsinogen concentrations
among Michigan newborns and implications
for cystic fibrosis newborn screening.
Pediatr Pulmonol. 2011;46(2):125-30.
28. Castellani C, Benetazzo MG, Bonizzato A,
Pignatti PF, Mastella G. Cystic fibrosis mutations
in heterozygous newborns with hypertrypsinemia
and low sweat chloride. Am J
Hum Genet. 1999;64(1):303-4.
29. Scotet V, Assael BM, Duguépéroux I, Tamanini
A, Audrézet MP, Férec C, et al. Time trends
in birth incidence of cystic fibrosis in two European
areas: data from newborn screening
programs. J Pediatr. 2008;152(1):25-32.
30. Yamaguchi A, Nepote JA, Kadivar M, Tagami Y,
Fukushi M, Kikuchi Y, et al. Allele specific PCR
with microfluorometry: application to the detection
of del F508 mutation in cystic fibrosis.
Clin Chim Acta. 2002;316(1-2):147-54.
31. Dequeker E, Cuppens H, Dodge J, Estivill X,
Goossens M, Pignatti PF, et al. Recommendations
for quality improvement in genetic
testing for cystic fibrosis. European Concerted
Action on Cystic Fibrosis. Eur J Hum Genet.
2000;8 Suppl 2:S2-24.
32. Dequeker E, Stuhrmann M, Morris MA; Casals
T, Castellani C, Claustres M, et al. Best
practice guidelines for molecular genetic
diagnosis of cystic fibrosis and CFTR-related
disorders updated European recommendations.
Eur J Hum Gen. 2009;17(1): 51-65.
33. Sarles J, Berthézène P, Le Louarn C, Somma
C, Perini JM, Catheline M, et al. Combining
immunoreactive trypsinogen and
pancreatitis-associated protein assays, a
method of newborn screening for cystic fibrosis
that avoids DNA analysis. J Pediatr.
2005;147(3):302-5.
34. Stopsack M, Hammermann J. Improved cut
off combination for IRT and PAP in Newborn
Screening for Cystic Fibrosis. Clin Biochem.
2011;44(7):545.
35. Sommerburg O, Lindner M, Muckenthaler
M, Kohlmueller D, Leible S, Feneberg R, et
al. Initial evaluation of a biochemical cystic
fibrosis newborn screening by sequential
analysis of immunoreactive trypsinogen
and pancreatitis-associated protein (IRT/
PAP) as a strategy that does not involve
DNA testing in a northern european population.
J Inherit Metab Dis. 2010;33(Suppl
2):S263-71.
36. Casals T, Ramos MD, Gimenez J, Larriba
S, Nunes V, Estivill X. High heterogeneity
for CF in Spanish families: 75% account
for 90% of chromosoms. Hum Genet.
1997;101(3):365-70.
37. Castellani C, Southern KW, Brownlee K,
Dankert Roelse J, Duff A, Farrell M, et al.
European best practice guidelines for cystic
fibrosis neonatal screening. J Cyst Fibros.
2009;8(3):153-73.
38. Borowitz D, Parad R, Sharp JK, Sabadosa
KA, Robinson KA, Rock MJ et al. Cystic Fibrosis
Foundation: Practice guidelines for
the management of infants with cystic fibrosis
transmembrane conductance regulator-related
metabolic syndrome during the
first two years of life and beyond. J Pediatr.
2009;155(6 Suppl):S106-16.
39. Sontag MK, Wright D, Beebe J, Accurso FJ,
Sagel SD. A new cystic fibrosis newborn
screening algorithm: IRT/IRT1↑/DNA. J Pediatr.
2009;155(5):618-22.
40. De Boeck K, Wilschanski M, Castellani C, Taylor
C, Cuppens H, Dodge J, et al. Cystic fibrosis:
terminology and diagnostic algorithms.
Thorax. 2006;61(7):627-35.
41. Mayell SJ, Munck A, Craig JV, Sermet I,
Brownlee KG, Schwarz MJ, et al. A European
consensus for the evaluation and
management of infants with an equivocal
diagnosis following newborn screening
for cystic fibrosis. J Cyst Fibros.
2009;8(1):71-8.
42. Gomez Lira M, Benetazzo MG, Marzari MG,
Bombieri C, Belpinati F, Castellani C, et al.
High frequency of cystic fibrosis transmembrane
regulator mutation L997F in patients
with recurrent idiopathic pancreatitis and in
newborns with hypertrypsinemia. Am J Hum
Genet. 2000;66(6):2013-4.
43. Castellani C, Massie J. Emerging issues in
cystic fibrosis newborn screening. Curr Opin
Pulm Med. 2010;16(6):584-90.
44. Barrio Gómez de Agüero MI, García
Hernández G, Gartner S; Grupo de Trabajo de
Fibrosis Quística. Protocolo de diagnostico y
seguimiento de los pacientes con fibrosis quistica.
An Pediatr (Barc). 2009;71(3):250-64.
45. Sermet-Gaudelus I, Mayell SJ, Southern
KW; European Cystic Finrosis Society
(ECFS), Neonatal Screening Working Group.
Guidelines on the early management of
infants diagnosed with cystic fibrosis following
newborn screening. J Cyst Fibros.
2010;9(5):323-9.
46. Stafler P, Davies JC, Balfour-Lynn IM, Rosenthal
M, Bush A. Bronchoscopy in cystic fibrosis
infants diagnosed by newborn screening.
Pediatr Pulmonol. 2011;46(7):696-700.
47. Gartner S, Casals T, Marin JL, Seculi JL,
Asensio O, Hernandez JL et al. Neonatal
screening in Cataluña: 10 years of experience.
J Cyst Fibros. 2010:9 (Suppl 1):S9.
48. Dodge JA. Why screen for cystic fibrosis?
A clinician’s view. Acta Paediatr. 1999;
88(432):28-32.